Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma

Documenti analoghi

• Response to ‘Letter to the Editor: “Lymphocyte‐Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis”’
  di: Tatsuya Sakane, et al.
  Pubblicazione: (2026)
• Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
  di: Tomomitsu Matono, et al.
  Pubblicazione: (2026)
• Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
  di: Tomomitsu Matono, et al.
  Pubblicazione: (2025)
• Development of a Predictive Model for Classifying Immune Checkpoint Inhibitor‐Induced Liver Injury Types
  di: Jun Kitadai, et al.
  Pubblicazione: (2025)
• Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
  di: Kazuhiro Nouso, et al.
  Pubblicazione: (2026)